{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T02:37:34Z","timestamp":1772937454014,"version":"3.50.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"DOI":"10.1007\/s11899-026-00775-4","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T08:34:35Z","timestamp":1772872475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms"],"prefix":"10.1007","volume":"21","author":[{"given":"Colette","family":"Hanna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Rizkallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Charbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shereen","family":"Sakkal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi G.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"775_CR1","unstructured":"Mikhail ES, Ghatol A. Hypereosinophilic syndrome. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 11 Jan 2024."},{"issue":"9","key":"775_CR2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","volume":"126","author":"AD Klion","year":"2015","unstructured":"Klion AD. How I treat hypereosinophilic syndromes. Blood. 2015;126(9):1069\u201377. https:\/\/doi.org\/10.1182\/blood-2014-11-551614.","journal-title":"Blood"},{"issue":"14","key":"775_CR3","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/cells13141180","volume":"13","author":"M Caminati","year":"2024","unstructured":"Caminati M, Brussino L, Carlucci M, et al. Managing patients with hypereosinophilic syndrome: A statement from the Italian society of Allergy, Asthma, and clinical immunology (SIAAIC). Cells. 2024;13(14):1180. https:\/\/doi.org\/10.3390\/cells13141180. Published 2024 Jul 11.","journal-title":"Cells"},{"key":"775_CR4","doi-asserted-by":"publisher","unstructured":"Morales-Camacho RM, Caballero-Vel\u00e1zquez T, Borrero JJ, Bernal R, Prats-Mart\u00edn C. Hematological Neoplasms with Eosinophilia. Cancers (Basel). 2024;16(2):337. Published 12 Jan 2024. https:\/\/doi.org\/10.3390\/cancers16020337","DOI":"10.3390\/cancers16020337"},{"issue":"9","key":"775_CR5","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1038\/s41375-023-01958-1","volume":"37","author":"G Metzgeroth","year":"2023","unstructured":"Metzgeroth G, Steiner L, Naumann N, et al. Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: Reevaluation of the defining characteristics in a registry-based cohort. Leukemia. 2023;37(9):1860\u20137. https:\/\/doi.org\/10.1038\/s41375-023-01958-1.","journal-title":"Leukemia"},{"issue":"11","key":"775_CR6","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328. https:\/\/doi.org\/10.1182\/blood.2022015850.","journal-title":"Blood"},{"issue":"9","key":"775_CR7","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3324\/haematol.11420","volume":"92","author":"M Baccarani","year":"2007","unstructured":"Baccarani M, Cilloni D, Rondoni M, et al. The efficacy of Imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica. 2007;92(9):1173\u20139. https:\/\/doi.org\/10.3324\/haematol.11420.","journal-title":"Haematologica"},{"issue":"7","key":"775_CR8","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and Histiocytic\/Dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319. https:\/\/doi.org\/10.1038\/s41375-022-01613-1.","journal-title":"Leukemia"},{"issue":"8","key":"775_CR9","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/ajh.26966","volume":"98","author":"SA Wang","year":"2023","unstructured":"Wang SA, Orazi A, Gotlib J, et al. The international consensus classification of eosinophilic disorders and systemic mastocytosis. Am J Hematol. 2023;98(8):1286\u2013306. https:\/\/doi.org\/10.1002\/ajh.26966.","journal-title":"Am J Hematol"},{"issue":"6","key":"775_CR10","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/his.15021","volume":"83","author":"L Saft","year":"2023","unstructured":"Saft L, Kvasnicka HM, Boudova L, Gianelli U, Lazzi S, Rozman M. Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: A workshop report with focus on novel entities and a literature review including paediatric cases. Histopathology. 2023;83(6):829\u201349. https:\/\/doi.org\/10.1111\/his.15021.","journal-title":"Histopathology"},{"key":"775_CR11","doi-asserted-by":"publisher","DOI":"10.4132\/jptm.2025.09.24","author":"B Aqil","year":"2025","unstructured":"Aqil B. What\u2019s new in hematopathology 2025: myeloid neoplasms in the WHO 5th edition and ICC. J Pathol Transl Med. 2025. https:\/\/doi.org\/10.4132\/jptm.2025.09.24.","journal-title":"J Pathol Transl Med"},{"issue":"16","key":"775_CR12","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1182\/blood.2023022417","volume":"145","author":"A Reiter","year":"2025","unstructured":"Reiter A, Metzgeroth G, Cross NCP. How I diagnose and treat myeloid\/lymphoid neoplasms with tyrosine kinase gene fusions. Blood. 2025;145(16):1758\u201368. https:\/\/doi.org\/10.1182\/blood.2023022417.","journal-title":"Blood"},{"issue":"5","key":"775_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s11899-024-00738-7","volume":"19","author":"J L\u00fcbke","year":"2024","unstructured":"L\u00fcbke J, Metzgeroth G, Reiter A, Schwaab J. Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals. Curr Hematol Malig Rep. 2024;19(5):208\u201322. https:\/\/doi.org\/10.1007\/s11899-024-00738-7.","journal-title":"Curr Hematol Malig Rep"},{"issue":"8","key":"775_CR14","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/10245332.2018.1446279","volume":"23","author":"K Umino","year":"2018","unstructured":"Umino K, Fujiwara SI, Ikeda T, et al. Clinical outcomes of myeloid\/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement. Hematology. 2018;23(8):470\u20137. https:\/\/doi.org\/10.1080\/10245332.2018.1446279.","journal-title":"Hematology"},{"issue":"5","key":"775_CR15","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/ajh.27287","volume":"99","author":"W Shomali","year":"2024","unstructured":"Shomali W, Gotlib J. World health organization and international consensus classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(5):946\u201368. https:\/\/doi.org\/10.1002\/ajh.27287.","journal-title":"Am J Hematol"},{"issue":"4","key":"775_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00277-023-05106-8","volume":"102","author":"Y Sun","year":"2023","unstructured":"Sun Y, Wang Q, Zhang X, et al. Molecular genetics and management of world health organization defined atypical chronic myeloid leukemia. Ann Hematol. 2023;102(4):777\u201385. https:\/\/doi.org\/10.1007\/s00277-023-05106-8.","journal-title":"Ann Hematol"},{"issue":"6","key":"775_CR17","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","volume":"146","author":"F Roufosse","year":"2020","unstructured":"Roufosse F, Kahn JE, Rothenberg ME, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;146(6):1397\u2013405. https:\/\/doi.org\/10.1016\/j.jaci.2020.08.037.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"775_CR18","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3324\/haematol.2011.047530","volume":"97","author":"CP Montano-Almendras","year":"2012","unstructured":"Montano-Almendras CP, Essaghir A, Schoemans H, et al. ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-\u03baB. Haematologica. 2012;97(7):1064\u201372. https:\/\/doi.org\/10.3324\/haematol.2011.047530.","journal-title":"Haematologica"},{"issue":"3","key":"775_CR19","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1002\/ajh.24273","volume":"91","author":"A Pardanani","year":"2016","unstructured":"Pardanani A, Lasho T, Barraco D, Patnaik M, Elala Y, Tefferi A. Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation. Am J Hematol. 2016;91(3):E10\u20131. https:\/\/doi.org\/10.1002\/ajh.24273.","journal-title":"Am J Hematol"},{"issue":"2","key":"775_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11899-015-0256-3","volume":"10","author":"FC Kuo","year":"2015","unstructured":"Kuo FC, Dong F. Next-generation sequencing-based panel testing for myeloid neoplasms. Curr Hematol Malig Rep. 2015;10(2):104\u201311. https:\/\/doi.org\/10.1007\/s11899-015-0256-3.","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"775_CR21","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1080\/10428194.2017.1397663","volume":"59","author":"P Strati","year":"2018","unstructured":"Strati P, Tang G, Duose DY, et al. Myeloid\/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018;59(7):1672\u20136. https:\/\/doi.org\/10.1080\/10428194.2017.1397663.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"775_CR22","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.6004\/jnccn.2020.0042","volume":"18","author":"AT Gerds","year":"2020","unstructured":"Gerds AT, Gotlib J, Bose P, et al. Myeloid\/Lymphoid neoplasms with eosinophilia and TK fusion Genes, version 3.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(9):1248\u201369. https:\/\/doi.org\/10.6004\/jnccn.2020.0042.","journal-title":"J Natl Compr Canc Netw"},{"issue":"22","key":"775_CR23","doi-asserted-by":"publisher","first-page":"33229","DOI":"10.18632\/oncotarget.8906","volume":"7","author":"SQ Qu","year":"2016","unstructured":"Qu SQ, Qin TJ, Xu ZF, et al. Long-term outcomes of Imatinib in patients with FIP1L1\/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. Oncotarget. 2016;7(22):33229\u201336. https:\/\/doi.org\/10.18632\/oncotarget.8906.","journal-title":"Oncotarget"},{"issue":"6","key":"775_CR24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/j.1398-9995.2009.01943.x","volume":"64","author":"S Salemi","year":"2009","unstructured":"Salemi S, Yousefi S, Simon D, et al. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia\/hypereosinophilic syndrome. Allergy. 2009;64(6):913\u20138. https:\/\/doi.org\/10.1111\/j.1398-9995.2009.01943.x.","journal-title":"Allergy"},{"issue":"3","key":"775_CR25","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/bloodadvances.2019001111","volume":"4","author":"G Metzgeroth","year":"2020","unstructured":"Metzgeroth G, Schwaab J, Naumann N, et al. Treatment-free remission in FIP1L1-PDGFRA-positive myeloid\/lymphoid neoplasms with eosinophilia after Imatinib discontinuation. Blood Adv. 2020;4(3):440\u20133. https:\/\/doi.org\/10.1182\/bloodadvances.2019001111.","journal-title":"Blood Adv"},{"issue":"3","key":"775_CR26","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41409-021-01553-x","volume":"57","author":"JC Hern\u00e1ndez-Boluda","year":"2022","unstructured":"Hern\u00e1ndez-Boluda JC, Pereira A, Zinger N, et al. Allogeneic hematopoietic cell transplantation in patients with myeloid\/lymphoid neoplasm with FGFR1-rearrangement: a study of the chronic malignancies working party of EBMT. Bone Marrow Transpl. 2022;57(3):416\u201322. https:\/\/doi.org\/10.1038\/s41409-021-01553-x.","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"775_CR27","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/s1535-6108(03)00108-9","volume":"3","author":"J Cools","year":"2003","unstructured":"Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to Imatinib in a murine model of FIP1L1-PDGFR\u03b1-induced myeloproliferative disease. Cancer Cell. 2003;3(5):459\u201369. https:\/\/doi.org\/10.1016\/s1535-6108(03)00108-9.","journal-title":"Cancer Cell"},{"issue":"12","key":"775_CR28","doi-asserted-by":"publisher","first-page":"4970","DOI":"10.1182\/blood-2006-01-0285","volume":"107","author":"N von Bubnoff","year":"2006","unstructured":"von Bubnoff N, Gorantla SP, Th\u00f6ne S, Peschel C, Duyster J. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood. 2006;107(12):4970\u20132. https:\/\/doi.org\/10.1182\/blood-2006-01-0285.","journal-title":"Blood"},{"issue":"414","key":"775_CR29","doi-asserted-by":"publisher","first-page":"eaao1690","DOI":"10.1126\/scitranslmed.aao1690","volume":"9","author":"EK Evans","year":"2017","unstructured":"Evans EK, Gardino AK, Kim JL, et al. A precision therapy against cancers driven by KIT\/PDGFRA mutations. Sci Transl Med. 2017;9(414):eaao1690. https:\/\/doi.org\/10.1126\/scitranslmed.aao1690.","journal-title":"Sci Transl Med"},{"issue":"7","key":"775_CR30","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","volume":"21","author":"MC Heinrich","year":"2020","unstructured":"Heinrich MC, Jones RL, von Mehren M, et al. Avapritinib in advanced PDGFRA D842V-mutant Gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020;21(7):935\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(20)30269-2.","journal-title":"Lancet Oncol"},{"key":"775_CR31","doi-asserted-by":"publisher","unstructured":"LiuY, Mi X, Gadde R, et al. FGFR1 Rearrangement Guides Diagnosis and Treatment of a Trilineage B, T, and Myeloid Mixed Phenotype Acute Leukemia. JCO Precis Oncol. 2020;4:PO.19.00402. Published 25 Aug 2020. https:\/\/doi.org\/10.1200\/PO.19.00402","DOI":"10.1200\/PO.19.00402"},{"key":"775_CR32","doi-asserted-by":"publisher","first-page":"1015792","DOI":"10.3389\/fonc.2022.1015792","volume":"12","author":"T Li","year":"2022","unstructured":"Li T, Zhang G, Zhang X, Lin H, Liu Q. The 8p11 myeloproliferative syndrome: genotypic and phenotypic classification and targeted therapy. Front Oncol. 2022;12:1015792. https:\/\/doi.org\/10.3389\/fonc.2022.1015792. Published 2022 Nov 3.","journal-title":"Front Oncol"},{"issue":"4","key":"775_CR33","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/ajh.26828","volume":"98","author":"MM Patnaik","year":"2023","unstructured":"Patnaik MM, Tefferi A. Atypical chronic myeloid leukemia and myelodysplastic\/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023;98(4):681\u20139. https:\/\/doi.org\/10.1002\/ajh.26828.","journal-title":"Am J Hematol"},{"issue":"7","key":"775_CR34","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1182\/blood-2016-08-693630","volume":"129","author":"J Gotlib","year":"2017","unstructured":"Gotlib J. How I treat atypical chronic myeloid leukemia. Blood. 2017;129(7):838\u201345. https:\/\/doi.org\/10.1182\/blood-2016-08-693630.","journal-title":"Blood"},{"issue":"12","key":"775_CR35","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","volume":"27","author":"J Gotlib","year":"2021","unstructured":"Gotlib J, Reiter A, Radia DH, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nat Med. 2021;27(12):2192\u20139. https:\/\/doi.org\/10.1038\/s41591-021-01539-8.","journal-title":"Nat Med"},{"issue":"1","key":"775_CR36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/leu.2012.188","volume":"27","author":"M Ren","year":"2013","unstructured":"Ren M, Qin H, Ren R, Cowell JK. Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities. Leukemia. 2013;27(1):32\u201340. https:\/\/doi.org\/10.1038\/leu.2012.188.","journal-title":"Leukemia"},{"issue":"23","key":"775_CR37","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/blood.V126.23.2812.2812","volume":"126","author":"L Sebastian Kreil","year":"2015","unstructured":"Sebastian Kreil L, Ad\u00e8s M, Bommer, et al. Limited efficacy of Ponatinib in myeloproliferative neoplasms associated with FGFR1 fusion genes. Blood. 2015;126(23):2812. https:\/\/doi.org\/10.1182\/blood.V126.23.2812.2812.","journal-title":"Blood"},{"issue":"5","key":"775_CR38","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(20)30109-1.","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"775_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1182\/blood-2021-148103","volume":"138","author":"J-J Jason Gotlib","year":"2021","unstructured":"Jason Gotlib J-J, Kiladjian A, Vannucchi, et al. A phase 2 study of Pemigatinib (FIGHT-203; INCB054828) in patients with myeloid\/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLN FGFR1). Blood. 2021;138(Supplement 1):385. https:\/\/doi.org\/10.1182\/blood-2021-148103.","journal-title":"Blood"},{"issue":"9","key":"775_CR40","doi-asserted-by":"publisher","first-page":"EVIDoa2500017","DOI":"10.1056\/EVIDoa2500017","volume":"4","author":"S Verstovsek","year":"2025","unstructured":"Verstovsek S, Kiladjian JJ, Vannucchi AM, et al. Pemigatinib for Myeloid\/Lymphoid neoplasms with FGFR1 rearrangement. NEJM Evid. 2025;4(9):EVIDoa2500017. https:\/\/doi.org\/10.1056\/EVIDoa2500017.","journal-title":"NEJM Evid"},{"issue":"6","key":"775_CR41","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/2040620712459746","volume":"3","author":"C Harrison","year":"2012","unstructured":"Harrison C, Vannucchi AM. Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Ther Adv Hematol. 2012;3(6):341\u201354. https:\/\/doi.org\/10.1177\/2040620712459746.","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"775_CR42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00277-014-2221-y","volume":"94","author":"J Schwaab","year":"2015","unstructured":"Schwaab J, Knut M, Haferlach C, et al. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol. 2015;94(2):233\u20138. https:\/\/doi.org\/10.1007\/s00277-014-2221-y.","journal-title":"Ann Hematol"},{"issue":"17","key":"775_CR43","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1200\/JCO.2012.46.4370","volume":"31","author":"E Rumi","year":"2013","unstructured":"Rumi E, Milosevic JD, Casetti I, et al. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol. 2013;31(17):e269\u201371. https:\/\/doi.org\/10.1200\/JCO.2012.46.4370.","journal-title":"J Clin Oncol"},{"issue":"1","key":"775_CR44","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","volume":"15","author":"HT Chifotides","year":"2022","unstructured":"Chifotides HT, Bose P, Verstovsek S. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol. 2022;15(1):7. https:\/\/doi.org\/10.1186\/s13045-021-01157-4. Published 2022 Jan 19.","journal-title":"J Hematol Oncol"},{"key":"775_CR45","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.2147\/OTT.S267001","volume":"14","author":"JA Waksal","year":"2021","unstructured":"Waksal JA, Tremblay D, Mascarenhas J. Clinical utility of fedratinib in myelofibrosis. Onco Targets Ther. 2021;14:4509\u201321. https:\/\/doi.org\/10.2147\/OTT.S267001. Published 2021 Aug 21.","journal-title":"Onco Targets Ther"},{"issue":"14","key":"775_CR46","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","volume":"380","author":"FL Kuang","year":"2019","unstructured":"Kuang FL, Legrand F, Makiya M, et al. Benralizumab for PDGFRA-Negative hypereosinophilic syndrome. N Engl J Med. 2019;380(14):1336\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1812185.","journal-title":"N Engl J Med"},{"issue":"5 suppl 2","key":"775_CR47","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.anai.2025.10.019","volume":"135","author":"P Ogbogu","year":"2025","unstructured":"Ogbogu P, Roufosse F, Akuthota P, et al. Benralizumab for patients with hypereosinophilic syndrome: a randomized, double-blind, placebo-controlled phase 3 trial (NATRON). Ann Allergy Asthma Immunol. 2025;135(5 suppl 2):S2\u20133. https:\/\/doi.org\/10.1016\/j.anai.2025.10.019.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"775_CR48","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","volume":"10","author":"ME Wechsler","year":"2022","unstructured":"Wechsler ME, Klion AD, Paggiaro P, et al. Effect of dupilumab on blood eosinophil counts in patients with Asthma, chronic rhinosinusitis with nasal Polyps, atopic Dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2022;10(10):2695\u2013709. https:\/\/doi.org\/10.1016\/j.jaip.2022.05.019.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"775_CR49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejca.2017.05.017","volume":"81","author":"A Bernard-Tessier","year":"2017","unstructured":"Bernard-Tessier A, Jeanville P, Champiat S, et al. Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies. Eur J Cancer. 2017;81:135\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.017.","journal-title":"Eur J Cancer"},{"issue":"18","key":"775_CR50","doi-asserted-by":"publisher","first-page":"6862","DOI":"10.3390\/ijms21186862","volume":"21","author":"E Cris\u00e0","year":"2020","unstructured":"Cris\u00e0 E, Nicolosi M, Ferri V, Favini C, Gaidano G, Patriarca A. Atypical chronic myeloid leukemia: where are we now? Int J Mol Sci. 2020;21(18):6862. https:\/\/doi.org\/10.3390\/ijms21186862. Published 2020 Sep 18.","journal-title":"Int J Mol Sci"},{"issue":"25","key":"775_CR51","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with Ivosidenib in IDH1-Mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1716984.","journal-title":"N Engl J Med"},{"issue":"6","key":"775_CR52","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","volume":"130","author":"EM Stein","year":"2017","unstructured":"Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722\u201331. https:\/\/doi.org\/10.1182\/blood-2017-04-779405.","journal-title":"Blood"},{"issue":"7","key":"775_CR53","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"issue":"11","key":"775_CR54","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41408-022-00744-z","volume":"12","author":"RS Komrokji","year":"2022","unstructured":"Komrokji RS, Singh AM, Ali NA, et al. Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome. Blood Cancer J. 2022;12(11):148. https:\/\/doi.org\/10.1038\/s41408-022-00744-z. Published 2022 Nov 4.","journal-title":"Blood Cancer J"},{"issue":"2","key":"775_CR55","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","volume":"33","author":"JE Cortes","year":"2019","unstructured":"Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without Glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019;33(2):379\u201389. https:\/\/doi.org\/10.1038\/s41375-018-0312-9.","journal-title":"Leukemia"},{"issue":"6","key":"775_CR56","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","volume":"30","author":"J Rod\u00f3n","year":"2024","unstructured":"Rod\u00f3n J, Damian S, Furqan M, et al. Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nat Med. 2024;30(6):1645\u201354. https:\/\/doi.org\/10.1038\/s41591-024-02934-7.","journal-title":"Nat Med"},{"issue":"12","key":"775_CR57","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","volume":"27","author":"DJ DeAngelo","year":"2021","unstructured":"DeAngelo DJ, Radia DH, George TI, et al. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nat Med. 2021;27(12):2183\u201391. https:\/\/doi.org\/10.1038\/s41591-021-01538-9.","journal-title":"Nat Med"},{"key":"775_CR58","unstructured":"Ruxolitinib in treating patients with hypereosinophilic syndrome or primary eosinophilic disorders. National Library of Medicine (U.S.), Identifier. NCT03801434. https:\/\/clinicaltrials.gov\/study\/NCT03801434"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00775-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-026-00775-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00775-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T08:34:36Z","timestamp":1772872476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-026-00775-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["775"],"URL":"https:\/\/doi.org\/10.1007\/s11899-026-00775-4","relation":{},"ISSN":["1558-822X"],"issn-type":[{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}